{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=25",
    "query": {
      "intervention": "Blinded (placebo)",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 2208,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T05:40:47.424Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02410343",
      "title": "Study of TV-1106 in Growth Hormone-Deficient Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "TV-1106",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-04-30",
      "completion_date": "2015-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 25,
      "location_summary": "Artesia, California • Fountain Valley, California • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410343"
    },
    {
      "nct_id": "NCT02519777",
      "title": "Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Placebo for maraviroc (MVC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir (DTG)",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc (MVC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2016-04-21",
      "completion_date": "2021-01-05",
      "has_results": true,
      "last_update_posted_date": "2022-04-22",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02519777"
    },
    {
      "nct_id": "NCT03374475",
      "title": "A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "JNJ-42847922 20mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-42847922 40mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 140,
      "start_date": "2018-01-05",
      "completion_date": "2019-04-29",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 3,
      "location_summary": "San Diego, California • San Marcos, California • Miami, Florida",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03374475"
    },
    {
      "nct_id": "NCT03887377",
      "title": "The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Scar",
        "Hypertrophic Scar",
        "Mammary Disorder"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxins",
          "type": "DRUG"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 22,
      "start_date": "2019-06-10",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-15",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887377"
    },
    {
      "nct_id": "NCT01604889",
      "title": "A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-03-29",
      "completion_date": "2017-01-20",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604889"
    },
    {
      "nct_id": "NCT03534297",
      "title": "Study of Dapansutrile Capsules in Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systolic Heart Failure"
      ],
      "interventions": [
        {
          "name": "dapansutrile capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olatec Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-05-16",
      "completion_date": "2019-11-21",
      "has_results": false,
      "last_update_posted_date": "2020-01-09",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03534297"
    },
    {
      "nct_id": "NCT04064242",
      "title": "Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "CMK389",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 62,
      "start_date": "2020-09-23",
      "completion_date": "2023-12-12",
      "has_results": true,
      "last_update_posted_date": "2025-04-13",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Gainesville, Florida • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04064242"
    },
    {
      "nct_id": "NCT05604131",
      "title": "Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myocardial Infarction Type 1"
      ],
      "interventions": [
        {
          "name": "Deferiprone Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rohan Dharmakumar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2022-11-08",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05604131"
    },
    {
      "nct_id": "NCT03005288",
      "title": "Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "BYM338 10 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 78,
      "start_date": "2017-02-01",
      "completion_date": "2019-05-08",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • Miami, Florida • Miami Lakes, Florida + 4 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03005288"
    },
    {
      "nct_id": "NCT07721922",
      "title": "Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD Exacerbation"
      ],
      "interventions": [
        {
          "name": "Revefenacin",
          "type": "DRUG"
        },
        {
          "name": "formoterol fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Sterile Normal Saline)",
          "type": "OTHER"
        },
        {
          "name": "Albuterol sulfate",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium Bromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2026-09-01",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-15T05:40:47.424Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07721922"
    }
  ]
}